Restricted accessCase reportFirst published online 2016-3
Preemptive antiretroviral therapy modifications for the management of potential clinically significant drug interactions with direct acting hepatitis C therapies
We report a case series of HIV/HCV co-infected patients who underwent preemptive antiretroviral therapy modifications to manage clinically significant drug interactions with HCV therapy. Among the 15 patients reviewed, all changed to a raltegravir-based regimen and none experienced a loss of virologic suppression or increase in HIV-RNA.
AASLD, IDSA, IAS–USA. Recommendations for testing, managing, and treating hepatitis C, www.hcvguidelines.org (2014, accessed 24 March 2014).
2.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf (2014, accessed 24 March 2014).
Sulkowski MS, Sherman DE, V Soriano, et al. Telaprevir in combination with Peginterferon Alfa-2a/Ribavirin in HCV/HIV co-infected patients: SVR24 final study results. In: 63rd annual meeting of the American association for the study of liver diseases (AASLD 2012), Boston, MA, 9–13 November 2012.
7.
Sulkowski M, Pol S, Cooper C, et al. Boceprevir + Pegylated interferon + Ribavirin for the treatment of HCV/HIV-coinfected patients: end of treatment (Week 48) interim results. In: 19th conference on retroviruses and opportunistic infections, Seattle, WA,5–8 March 2012.
8.
MartinezELarrousseMLlibreJM. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS2010; 24: 1697–1707.
9.
EronJYoungBCooperD. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomized controlled trial. Lancet2010; 375: 396–407.
